Chelators As Antineuroblastomas Agents

Overview

Journal Physiol Res

Specialty Physiology

Date 2023 Oct 27

PMID 37888971

Authors

C W DAcunto

H Gbelcova

R Kaplanek

M Pospisilova

M Havlik

T Ruml

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma represents 8-10 % of all malignant tumors in childhood and is responsible for 15 % of cancer deaths in the pediatric population. Aggressive neuroblastomas are often resistant to chemotherapy. Canonically, neuroblastomas can be classified according to the MYCN (N-myc proto-oncogene protein) gene amplification, a common marker of tumor aggressiveness and poor prognosis. It has been found that certain compounds with chelating properties may show anticancer activity, but there is little evidence for the effect of chelators on neuroblastoma. The effect of new chelators characterized by the same functional group, designated as HLZ (1-hydrazino phthalazine), on proliferation (WST-1 and methylene blue assay), cell cycle (flow cytometry), apoptosis (proliferation assay after use of specific pharmacological inhibitors and western blot analysis) and ROS production (fluorometric assay based on dichlorofluorescein diacetate metabolism) was studied in three neuroblastoma cell lines with different levels of MYCN amplification. The molecules were effective only on MYCN-non-amplified cells in which they arrested the cell cycle in the G0/G1 phase. We investigated the mechanism of action and identified the activation of cell signaling that involves protein kinase C.

References

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

Fan L, Iyer J, Zhu S, Frick K, Wada R, Eskenazi A . Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells. Cancer Res. 2001; 61(3):1073-9. View

Kojima M, Hiyama E, Fukuba I, Yamaoka E, Ueda Y, Onitake Y . Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma. Pediatr Surg Int. 2013; 29(11):1139-45. DOI: 10.1007/s00383-013-3374-9. View

Richardson D . Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr Med Chem. 2005; 12(23):2711-29. DOI: 10.2174/092986705774462996. View

Abdelaal G, Veuger S . Reversing oncogenic transformation with iron chelation. Oncotarget. 2021; 12(2):106-124. PMC: 7825639. DOI: 10.18632/oncotarget.27866. View

DAcunto C, Kaplanek R, Gbelcova H, Kejik Z, Briza T, Vasina L . Metallomics for Alzheimer's disease treatment: Use of new generation of chelators combining metal-cation binding and transport properties. Eur J Med Chem. 2018; 150:140-155. DOI: 10.1016/j.ejmech.2018.02.084. View

Donfrancesco A, Deb G, Dominici C, Angioni A, Caniglia M, De Sio L . Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol. 1992; 15(4):319-22. DOI: 10.1097/00000421-199208000-00009. View

Gottwald E, Schuh C, Drucker P, Haenni D, Pearson A, Ghazi S . The iron chelator Deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability. Sci Rep. 2020; 10(1):1577. PMC: 6994599. DOI: 10.1038/s41598-020-58386-9. View

Whitnall M, Howard J, Ponka P, Richardson D . A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A. 2006; 103(40):14901-6. PMC: 1595448. DOI: 10.1073/pnas.0604979103. View

10.

Shen L, Zhao H, Du J, Wang F . Anti-tumor activities of four chelating agents against human neuroblastoma cells. In Vivo. 2005; 19(1):233-6. View

11.

Keer H, Kozlowski J, Tsai Y, Lee C, McEwan R, Grayhack J . Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J Urol. 1990; 143(2):381-5. DOI: 10.1016/s0022-5347(17)39970-6. View

12.

Blatt J, Stitely S . Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res. 1987; 47(7):1749-50. View

13.

Silber J, Evans A, Fridman M . Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. Cancer Res. 1991; 51(5):1426-33. View

14.

Richardson D, Ponka P . The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta. 1997; 1331(1):1-40. DOI: 10.1016/s0304-4157(96)00014-7. View

15.

Macsek P, Skoda J, Krchniakova M, Neradil J, Veselska R . Iron-Chelation Treatment by Novel Thiosemicarbazone Targets Major Signaling Pathways in Neuroblastoma. Int J Mol Sci. 2022; 23(1). PMC: 8745636. DOI: 10.3390/ijms23010376. View

16.

Ho V, BUNN H . Effects of transition metals on the expression of the erythropoietin gene: further evidence that the oxygen sensor is a heme protein. Biochem Biophys Res Commun. 1996; 223(1):175-80. DOI: 10.1006/bbrc.1996.0865. View

17.

Bajbouj K, Shafarin J, Hamad M . High-Dose Deferoxamine Treatment Disrupts Intracellular Iron Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines. Technol Cancer Res Treat. 2018; 17:1533033818764470. PMC: 5865460. DOI: 10.1177/1533033818764470. View

18.

Choi E, Lee S, Oh H, Kim Y, Choi E, Kim S . Involvement of protein kinase Cdelta in iron chelator-induced IL-8 production in human intestinal epithelial cells. Life Sci. 2006; 80(5):436-45. DOI: 10.1016/j.lfs.2006.09.044. View

19.

Richardson D, Kalinowski D, Lau S, Jansson P, Lovejoy D . Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta. 2008; 1790(7):702-17. DOI: 10.1016/j.bbagen.2008.04.003. View

20.

Bierings M, Baert M, van Eijk H, van Dijk J . Transferrin receptor expression and the regulation of placental iron uptake. Mol Cell Biochem. 1991; 100(1):31-8. DOI: 10.1007/BF00230807. View